The development of effective RT-QuIC assays in a diverse range of inherited prion diseases (IPDs) is of great interest in the context of future clinical trials of disease-modifying therapeutics targeting PrP in asymptomatic mutation carriers. The gene discussed is PRNP; the disease is prion disease.